All In MedTech

Device Trial Radar · NCT05585476

A Laser and Topical Treatment Combination in the Vulvo-vaginal Atrophy Management in Breast Cancer Patients.

Effectiveness of C02 Microfractionated Laser in Conjunction With Topical Regenerative Therapy in the Management of Vulvo-vaginal Atrophy in Patients With a History of Breast Cancer. Randomized Experimental and Comparative Study.

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 195 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

195

Planned (sponsor's estimate)

Start

Oct 15, 2025

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Lumenis Be Ltd.; Mucosa Innovations, S.L.
First posted
Oct 18, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Female only, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The genito-urinary syndrome of menopause severely affects patients with a history of gynecological cancer, especially those diagnosed with breast cancer. At the present time, we do not have solid scientific evidence on treatments that can be effective and safe to address this pathology. Based on the above, we have developed our working hypothesis where it is postulated that the microfractionated laser treatment of C02, in conjunction with topical regenerative treatment, constitute an effective alternative in the management of vulvo-vaginal atrophy in oncological patients who have contraindicated hormonal treatments.

Conditions

  • Female Urogenital Diseases
  • Breast Cancer Female

Interventions

  • C02 microablative laserDevice

    The C02 microablative laser was the first to be used in the treatment of menopausal genitourinary syndrome. Its mechanism of action is based on the emission of light at a wavelength of 10600nm that is absorbed by the water molecules contained in the vaginal mucosa, leading to local remodeling of connective tissue and neoformation of collagen, elastic fibers and other components of the extracellular matrix.

  • Regenerative topical treatmentCombination product

    It is a moisturizing and regenerating gel whose active ingredients are olive oil, trimethylglycine and xylitol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence of symptoms at the vulvovaginal level and their intensityTime frame: From prior consultation at the beginning of treatment to 6 months after it ends.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.